• Version
• Download 890
• File Size 515.83 KB
• File Count 1
• Create Date August 24, 2021
• Last Updated August 24, 2021

Position Statement: Demanding Access to Existing and Upcoming Gene Therapies for Beta Thalassaemia

The Thalassaemia International Federation (TIF) is expressing its grave disappointment over the recent announcement of Bluebird Bio, concerning the “wind-down” of its operations in Europe and the exclusive disposal of its gene therapy for beta thalassaemia (Zynteglo™) in the United States.

 

Attached Files